Wegovy vs Mounjaro in the UK: What NICE Actually Approved

Type "Wegovy vs Mounjaro" into a search box and the results read like a contest: which is stronger, which wins, which should you ask for. It is an understandable question and almost entirely the wrong one. These are two prescription medicines for a chronic condition, each assessed on its own terms by the bodies that decide what the NHS will fund. The useful thing to understand is not which "beats" the other, but what each one is, what NICE actually said about it, and why that is a clinical question rather than a shopping decision.

So this is a difference-explainer, written in plain terms. It will not crown a winner, because that is not how medicines for obesity are chosen, and anyone selling you a league table is selling you the wrong frame.

What are Wegovy and Mounjaro?

Wegovy is a brand name for semaglutide; Mounjaro is a brand name for tirzepatide. Both are weekly injections, and both work on gut-hormone pathways involved in appetite and blood sugar — but they are not the same molecule.

Semaglutide acts on a single incretin receptor, GLP-1. It mimics a gut hormone that, among other effects, dampens appetite and slows stomach emptying, and the drugs built around it reshaped what was achievable with medicine alone in obesity. Tirzepatide acts on two receptors at once — GLP-1 and GIP — which is why it is often described as a "dual-incretin" drug. (I have written separately about what adding that second hormone changes, and what it doesn't.) The short version: same broad family, overlapping but not identical biology.

It is also worth flagging a naming tangle that confuses people. Semaglutide is sold as Wegovy for weight management and as Ozempic for type 2 diabetes; tirzepatide is sold as Mounjaro across both indications in the UK. The brand on the box reflects the licensed use and dose, not a different drug.

What did NICE actually approve?

In general terms, NICE recommended both semaglutide and tirzepatide as options for managing overweight and obesity in adults — but only within defined criteria, and only alongside a structured programme of dietary and lifestyle support, not as a standalone fix.

NICE — the National Institute for Health and Care Excellence — is the body that assesses whether a treatment represents good enough value and benefit to be funded on the NHS in England. Its technology appraisals for these medicines set out who is eligible: broadly, people above certain body-mass-index thresholds, often with weight-related health conditions, and accessed through specified NHS routes. The exact thresholds, the settings in which each can be started, and the phased rollout differ between the two appraisals and have been refined over time, which is part of why a simple side-by-side misleads.

Two things matter more than the precise numbers. First, a NICE recommendation is about NHS funding and eligibility — it is a population-level judgement about cost and benefit, not a verdict that one drug is "better" for you specifically. Second, the criteria exist because these are treatments for a chronic condition in defined groups, supervised over time, not appetite suppressants to be handed out on request.

What the trial evidence actually shows

Both medicines have large randomised trials behind them showing substantial average weight loss alongside lifestyle support — and "average" is the load-bearing word.

Semaglutide's weight-management evidence came chiefly from the STEP programme; tirzepatide's from the SURMOUNT programme. Both produced figures that genuinely changed the conversation, with tirzepatide's higher doses reaching, on average, into territory previously associated mainly with surgery. It is tempting to read across from those headline percentages and declare a winner.

Resist it, for reasons that are not pedantic. These trial numbers are averages with wide individual variation; they were achieved with structured diet and activity support, not the drug in isolation; the participants were selected and closely monitored; and head-to-head comparisons between drugs are a different and more demanding kind of study than comparing two separate trials' headline figures. Beyond that, the outcomes that matter most over a lifetime — heart attacks, strokes, years of healthy life — accrue over far longer horizons than weight-loss trials run, and that evidence builds slowly. The early results are striking. They are not the same as decades of outcome data, and they do not tell any individual which medicine fits them.

Why "which is better" is the wrong question

The right medicine for a given person is not the one with the biggest number in a trial. It is the one that fits their particular situation — and that genuinely varies from person to person.

Several things differ between these medicines and between the people taking them. What is the treatment actually for — obesity alone, or obesity with type 2 diabetes? What other conditions and medications are in play? How well does someone tolerate the gradual dose escalation, given that gut side effects are common across the whole class? Which medicine is available and licensed for their situation, and through which route? A drug with a slightly higher average effect that someone cannot tolerate is, for them, worse than one they can. This is precisely why the choice belongs with a prescriber who knows the person's full history — and why "the strongest one" is not a meaningful answer.

Practical takeaways

• Wegovy is semaglutide (single-incretin, GLP-1); Mounjaro is tirzepatide (dual-incretin, GLP-1 and GIP). Same family, different molecules.
• NICE recommended both for managing obesity in adults within defined eligibility criteria and alongside structured lifestyle support — a funding-and-eligibility judgement, not a verdict on which suits you.
• Both have large trials showing substantial average weight loss; those are averages, achieved with lifestyle support, over limited horizons, and not a head-to-head ranking.
• Which medicine fits a person depends on their full picture — other conditions, medications, tolerance and what they are being treated for — and is a clinical decision.

What this doesn't mean

It does not mean one of these is "the best" weight-loss drug, or that a bigger trial average translates into a better outcome for any specific person. A NICE recommendation is not a personal prescription, and eligibility criteria are not a menu to choose from. Nor does any of this imply these medicines are cosmetic — they are long-term, supervised treatment for a chronic condition.

When to speak to your GP

Whether either medicine is appropriate, and which, is a decision for a qualified prescriber who can assess your full medical history — not something to settle from a comparison article. If you are taking one of these medicines and develop severe or persistent abdominal pain, repeated vomiting, signs of dehydration, or any symptom that worries you, seek medical advice promptly.

A closing thought

The framing battle around these drugs — Wegovy versus Mounjaro, as if picking a phone — does a quiet disservice. It turns a careful clinical decision, made with someone who knows your history, into a consumer face-off, and in doing so it strips out the very context that makes the decision a good one. The more interesting truth is duller and more useful: there is no universal winner, only a medicine that fits a particular person, chosen with a clinician who can see the whole picture.

Further reading and sources

• NICE TA875 — semaglutide for managing overweight and obesity
• NICE TA1026 — tirzepatide for managing overweight and obesity
• STEP programme — randomised trials of semaglutide for weight management
• SURMOUNT programme — randomised trials of tirzepatide for weight management
• NHS — overview of weight-loss medicines and eligibility
• MHRA — licensing of semaglutide and tirzepatide products

Brand names are mentioned for identification only. The author has no commercial relationship with any manufacturer, and nothing here is an advertisement for, or recommendation to obtain, any medicine.